Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 31%
Sell 15%
Strong Sell 0%

Bulls say

CME Group's projected earnings are expected to benefit from a potential 4%-5% boost due to the introduction of new pricing strategies and customer expansion initiatives, particularly through partnerships like FanDuel. The company's anticipation of revenues exceeding $300 million annually from new offerings indicates significant growth opportunities, which could further enhance EPS in 2026 and beyond. With the recent adjustments to EPS forecasts and increased optimism surrounding prediction markets, CME Group's stock outlook remains robust, supported by its strategic acquisitions and its established position in trading and clearing S&P futures contracts.

Bears say

CME Group faces significant regulatory risks that may lead to reduced trading volumes, as potential changes in margin requirements and speculation limitations are under consideration by regulators. Additionally, uncertainties surrounding customer demand, competitive positioning, and unforeseen developments in management or accounting practices could adversely impact anticipated revenues and earnings. The firm's exposure to credit risk from third-party clearing members also poses a threat to its working capital, further complicating its financial outlook.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Jan 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $288, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $288, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.